euroPLX 43 Berlin

Registration Fee and Conditions

Delegates' Comments

"…four times as much for half the price…"
Anke Rau and Dr. Norbert Rau

"euroPLX is sometimes tough and intense…"
Sebastien Sanial and Malgorzata Derewianka

"…a very efficient way to meet in one-to-one meetings…"
Dr. Peter Komnick and Dr. Silke Behne

"We are Platinum Sponsors of euroPLX 49 Istanbul, because…"
Rich DiCicco

"We became a returning attendee as we've never left empty-handed…"
Kees Trommelen

"…get focused on the business...just business!"
Dragan Lutz and Mario Vlasic

"I have successfully used the euroPLX meetings for licensing-in and licensing-out…"
Dr. Satyendra Kumar

"…meet your business partners at the well organized events…"
Peter van Hoogstraten and Paul C. Borghouts

"…a highly effective and pleasant way to meet…"
Ronald Kriek and Wouter Hanegraaf

"…interact with so many companies…"
Simona Aganovic and Guy Clark

"We get value for our money…"
Vilas Nagare and Sundeep V. Bambolkar

"It’s the best partnering event…"
Jinang Parekh and Vijay Agarwal

"…the only partnering conference that covers all aspects of business development…"
Dr. Hubert Ridolphi and Dr. Gerrit Hagens

"…no better event than euroPLX to enlarge your network in the
pharmaceutical business…"
Gilbert Adatte

"...good place to expand your international network..."
Ramon Brusco

"…we wouldn’t do that if there were no results!"
Patrick Tichy

"…one of the few events which attracts a cross section of attendees from all pharmaceutical sectors…"
Daniel Jones

"…the best time and cost effective way to meet new partners."
Nuray Acar and Mutlu Topal

"There is no end to new challenges at euroPLX"
Ruud Koolen

"…a basis for excellent business."
Ana Paula Branco and José Roberto Pereira

"euroPLX is the most cost-effective and time-saving way…"
David Zubeldía

"…good opportunity for meeting with many relevant players…"
Dietmar Jannaschk and Gemma Mogas

"…euroPLX is the perfect place…"
Gustavo Samojeden and Hernán Bouzada

"…a tremendous opportunity to meet new partners…"
Marc Alvarez

"…efficient and fruitful one-to-one discussions…"
Sylvie Fondanayche

"We are not aware of any other event where you can meet so many interesting partners…"
Holger and Kai Schleenhain

"I rate euroPLX very high…"
Reynhardt Van As

"euroPLX is the best pharma meeting…"
Santiago, Mar, and Josémaria Calzada

"…very good opportunity to meet existing and new business partners…"
Agnes Olszanowski and Dr. Marian Takac

"I never leave euroPLX empty-handed."
Wendell Clayton

"…the best possible way to contact a large number of people…" Shala Fardaei and Ineke Braat

"It was in this forum that we forged some of our major alliances…" Nimit Jhaveri and Biplab Kar

"…we have made a lot of money on euroPLX deals…"
Rich DiCicco

"…an ideal opportunity to meet…"
Andreas Wagner & Michel Blanc

"…extremely time and cost efficient way to make new business contacts…"
Wolfgang Bäurle

"euroPLX is the most efficient event I know…"
Patsy Carney

"…the most efficient of the Business Development forums…"
Roland Brown

"…a tremendous opportunity to network intensely…"
Elzbieta Weston & Jacek Plucienniczak

Sponsors for Recent Meeting

Dinner Sponsors

Media Sponsors

euroPLX 43 Berlin

137 Companies From 37 Countries

Click to view registered companies

Almost exactly 15 years after the first euroPLX Meeting (then called European Pharma Licensing Meeting) was held on 20 June 1995 in Frankfurt, Germany, with only 11 nations represented, euroPLX has become the pharma industry's most international partnering event with delegates from regularly more than 35 countries attending: euroPLX 43 Berlin saw almost 200 delegates of 137 companies from 37 countries and four continents.

An astonishing 28.5% of all companies participating in Berlin attended a euroPLX Meeting for the very first time - after 15 years!

The leading partnering event for pharma and biopharma business development delivered an average of 23.2 pre-scheduled one-on-one negotiations per participating company on two conference days, in addition to numerous appointments which were scheduled on site.

The interest of the participating pharma and biotech companies was focused on patented (61%) and generic drugs (89%) as well as biosimilars (23%), and the growing interest in preclinical and early clinical stages reflected the presence of biotech and research specialist companies. Nevertheless, approved drugs attracted most of the interest, in particular prescription drugs.